Tyra Biosciences, Inc. (TYRA) News

Tyra Biosciences, Inc. (TYRA): $17.32

0.32 (+1.88%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add TYRA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#177 of 360

in industry

Filter TYRA News Items

TYRA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest TYRA News From Around the Web

Below are the latest news stories about TYRA BIOSCIENCES INC that investors may wish to consider to help them evaluate TYRA as an investment opportunity.

Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the 2023 Jefferies London Healthcare Conference, taking place November 14-16, 2023.

Yahoo | November 8, 2023

Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30, 2023 and highlighted recent corporate progress.

Yahoo | November 7, 2023

Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that TYRA will deliver oral presentations on TYRA-300 for achondroplasia at the American Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG) 2023 annual meetings.

Yahoo | September 21, 2023

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | September 17, 2023

Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate at the 2023 Cantor Global Healthcare Conference, taking place September 26-28, 2023, in New York, NY.

Yahoo | September 12, 2023

Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended June 30, 2023 and highlighted recent corporate progress.

Yahoo | August 10, 2023

Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead precision medicine program, TYRA-300, for the treatment of achondroplasia.

Yahoo | August 1, 2023

Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength

Tyra Biosciences, Inc. (TYRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Yahoo | June 16, 2023

Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet

The consensus price target hints at a 52.2% upside potential for Tyra Biosciences, Inc. (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | June 7, 2023

Tyra Biosciences to Participate in Upcoming Investor Conferences

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences:

Yahoo | May 25, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!